Hematological Malignancies
Conditions
Keywords
Apoptosis, FAS Ligand, Bone marrow transplantation, GvHD, Stem cells
Brief summary
Interventional, open label, Phase I/II, Safety and Proof-of-Concept Study, with a follow up period of 180 days after the transplantation of ApoGraft.
Detailed description
ApoGraft product is a mobilized peripheral blood cell product of a matched Related donor, collected via apheresis, which is exposed to the apoptotic mediator Fas Ligand (CD95L) prior to transplantation (Ex Vivo). The study is designed to address the aspects of engraftment and Prevention of Acute Graft versus Host Disease (aGvHD) rate and/or severity in 12 Patients STUDY DESIGN: This is a phase 1/2, open-label, proof-of-concept, staggered 4-cohort clinical study. Each cohort will include 3 patients with hemato-oncology disorders eligible for allogeneic HLA-matched HSCT. Patients in all cohorts will undergo similar study procedures and evaluation. The cohorts will differ from each other in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplantation and HSCT, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3 and 100 ng/ml APO010 in Cohort 4. APO010 is washed-out as part of the ApoGraft process and only trace amounts of APO010 are present in the final ApoGraft product The study consists of a screening phase (subject and donor clinical assessment and screening tests), transplantation of ApoGraft, and a follow-up period of 180 days during and after hospitalization. The study will progress from one cohort to the next based on an independent data safety monitoring board (DSMB) review and analysis of safety data
Interventions
BIOLOGICALAllogeneic MPBC transplantation from matched related donor
Sponsors
Cellect Biotechnology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Recipient/patient main inclusion criteria: 1. Adult male or female subjects, 18-70 years of age. 2. Subjects are eligible for allogeneic HLA-matched related HSCT for any hematological malignancies for which transplantation is appropriate with corresponding related donor. One of the following hemato-oncology disorders diagnosis is required: * Acute myelogenous leukemia (AML) and Acute lymphoblastic leukemia (ALL) in 1st or subsequent complete remission (CR) * Non-Hodgkin's disease (NHD) in CR by CT or PET/CT * Hodgkin's disease (HD) in 1st or subsequent CR by CT or PET/CT * Intermediate, High or Very High Risk Myelodysplastic syndrome (MDS) (IPSS-R criteria) 3. The donor and recipient must have full match at the HLA A, B, C, DR and DQ loci. 4. ECOG performance status score 0-1 at time of the screening visit. 5. Subjects must have adequate organ function as defined in the study protocol 6. Signed written informed consent to participate in the study. 7. If female of childbearing potential, agree to use an acceptable method of birth control or be surgically sterile, and have a negative pregnancy test. Donor main inclusion criteria: 1. Adult male or female subjects, 18-65 years of age. 2. Donor criteria according to standard WMDA criteria for donor selection. 3 Must have full match at the HLA A, B, C, DR and DQ loci with the recipient. 4\. Signed written informed consent Recipient/patient main
Exclusion criteria
1. Use of non-myeloabletive conditioning. 2. Uncontrolled infections including sepsis, pneumonia with hypoxemia, persistent bacteremia, or meningitis within two weeks of the screening visit. 3. Current known acute or chronic infection with HBV or HCV. 4. Known human immunodeficiency virus (HIV) infection or AIDS. 5. Subjects with severe or symptomatic restrictive or obstructive lung disease or respiratory failure requiring ventilator support. 6. Subjects with other concurrent severe and/or uncontrolled medical condition, which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive cardiac failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months and chronic liver or renal disease. 7. Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or any chronic condition susceptible, in the opinion of the investigator, of interfering with the conduct of the study. 8. Organ allograft or previous history of allogeneic stem cell transplantation. 9. Pregnancy or lactation. Donor main
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall incidence, frequency and severity of adverse events (AEs) potentially related to the product during the study | 180 days from transplantation |
Secondary
| Measure | Time frame |
|---|---|
| Time of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3 | 28 days from transplantation |
| Rate of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3 | 28 days from transplantation |
| Time of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days | 180 days from transplantation |
| Rate of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days | 180 days from transplantation |
| Determination of the optimal dose of FasL concentration that facilitates the biological activity of the ApoGraft process | 180 days from transplantation |
| Time to development of aGvHD | 180 days from transplantation |
| Non-relapse mortality | 180 days from transplantation |
| Proportion of patients with disease relapse | 180 days from transplantation |
| Proportion of patients with progression free and overall survival | 180 days from transplantation |
| Incidence to development of aGvHD | 180 days from transplantation |
Countries
Israel
Contacts
Primary ContactShai Yarkoni, MD
Outcome results
None listed